Welcome to our dedicated page for Renalytix Plc SEC filings (Ticker: RNLXY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page is dedicated to regulatory and disclosure documents related to Renalytix plc (RNLXY), an artificial intelligence-enabled in vitro diagnostics and laboratory services company focused on kidney disease. While specific SEC filings may not be listed here for every period, investors use this section to locate key documents that explain how the company reports on its operations, financial condition, and capital structure.
For a company like Renalytix, which develops and commercializes the FDA-authorized kidneyintelX.dkd prognostic test for adults with type 2 diabetes and chronic kidney disease stages 1–3b, formal filings and disclosures provide context on topics such as revenue from test ordering and processing, research and development spending, and general and administrative costs. Company announcements have also discussed equity financings, restructuring of liabilities, and the decision to move its American Depositary Shares from Nasdaq to the OTCQB Venture Market, actions that are typically documented or referenced in regulatory filings.
On Stock Titan, Renalytix filings are paired with AI-powered summaries that help explain the contents of lengthy documents in plain language. When available, investors can use these tools to quickly understand themes in annual and periodic reports, capital raises, and listing changes, as well as to identify disclosures related to its kidneyintelX.dkd test and broader kidney health strategy.
Filings shown on this page are updated as they are released through official channels. Users can review them alongside AI-generated explanations to form a clearer view of Renalytix’s financial profile, risk factors, and progress in commercializing its AI-enabled prognostic testing for chronic kidney disease.
Renalytix plc’s major shareholder group has fallen below the 5% ownership threshold. Jefferson River Capital LLC and related parties now report beneficial ownership of 19,644,391 Ordinary Shares, or 4.5% of the class, based on 437,018,680 Ordinary Shares outstanding as of November 3, 2025.
The Hamilton E. James 2003 Children's Trust and David R. James each report beneficial ownership of 19,406,043 Ordinary Shares, representing 4.4% of the class. The filing states that each reporting person ceased to be the beneficial owner of more than 5% of Renalytix’s Ordinary Shares on November 3, 2025.